Drug Trial Radar · NCT07637851
Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
43
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Sep 2028
Study completion Apr 2030
Sponsor
- Lead sponsor
- ARCAGY/ GINECO GROUPAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jun 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to assess the safety and efficacy of ubamatamab in combination with first-line chemotherapy in patients with ovarian cancer. The main questions it aims to answer are: * What is the safety profile of ubamatamab when administered with carboplatin-paclitaxel ± bevacizumab? * What is the objective response rate after three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab? Participants will: * Receive three cycles of ubamatamab in combination with carboplatin-paclitaxel ± bevacizumab, followed by maintenance therapy with ubamatamab ± bevacizumab for up to 15 months, depending on HRD status and disease response after the initial treatment cycles. * Attend regular clinic visits throughout the treatment period for checkups and tests
Conditions
- Ovarian Cancer
Interventions
UbamatamabDrug
Dosage form: Solution for perfusion Dosage: 5 mg/mL; 50 mg/mL Frequency: administration every three weeks Treatment duration: 15 months
ChemotherapyDrug
Carboplatin + Paclitaxel administered at each cycle of 21 days (in total 3 cycles).
BevacizumabDrug
Bevacizumab administered at each cycle of 21 days (3 cycles in total) then during maintenance therapy every 3 weeks.
GCSFDrug
Administered at each cycle during the 3 first cycles of the drug combination (chemotherapy + bevacizumab + ubamatamab).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring periodTime frame: Up to 4 weeks of treatment
- Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring periodTime frame: Up to 4 weeks of treatment
- Safety run-in phase I : Safety and recommended dose for phase II trial during the Dose-limiting toxicities monitoring periodTime frame: From Cycle 1 Day 1 of the first patient included to Cycle 3 Day 1 of the sixth patient included (each cycle is 21 days) (Safety and Tolerability)
- Efficacy phase II partTime frame: 1 month after Cycle 3 Day 1 of the sixth patient included (each cycle is 21 days).
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Institut Bergonié
Bordeaux, France
Centre François Baclesse
Caen, France
Centre Georges François Leclerc
Dijon, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
ICM Val d'Aurelle
Montpellier, France
HCL - Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Centre Eugène Marquis
Rennes, France
ICO - Centre René Gauducheau
Saint-Herblain, France
Hôpital de Hautepierre
Strasbourg, France
Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.